Cash, cash equivalents and short-term investments as of June 30, 2024, were $7.1M. Monopar projects that its current funds will be sufficient to continue operations at least through August 31, 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNPR:
- Monopar Therapeutics Begins Pioneering MNPR-101-Zr Trial
- Monopar announces first patient enrolled in Phase 1 trial of MNPR-101-Zr
- Monopar announces acceptance of MNPR-101-RIT abstract for EANM 2024
- Monopar Announces MNPR-101-RIT Abstract Accepted as a Top-Rated Oral Presentation at EANM’24
- Monopar Therapeutics Enhances Alliance with NorthStar Medical